Indian Journal of Urology Users online:3742  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

Year : 2003  |  Volume : 19  |  Issue : 2  |  Page : 113-116

Doxazocin in management of benign prostatic hyperplasia

Department of Urology, Safdarjang Hospital, New Delhi, India

Correspondence Address:
N K Mohanty
D-11/87, West Kidwai Nagar, New Delhi - 110 023
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions


A total 220 patients with benign prostatic hyperplasia (BPH) but not having absolute indication for surgery were enrolled for 8 weeks single label study, using doxazocin (Doxacard) 4 mg daily for their features of prostatism, with a six month follow up. The study revealed an improve­ment of 90% in their symptoms at the end of the study with an increase of maximum flow rate (MFR) by 5-5.5 ml/sec and average flow rate (AFR) 2.5-3 ml/sec. Adverse effects were minimum and patient compliance was very good with good drug tolerability. Our study strongly supports the use of doxazocin as an alternative in the management of uncomplicated BPH with hypertension.

Keywords: α - alderneric, doxazocin, Doxacard.

How to cite this article:
Mohanty N K, Arora R P, Jha A K, Pal S S. Doxazocin in management of benign prostatic hyperplasia. Indian J Urol 2003;19:113-6

How to cite this URL:
Mohanty N K, Arora R P, Jha A K, Pal S S. Doxazocin in management of benign prostatic hyperplasia. Indian J Urol [serial online] 2003 [cited 2022 May 26];19:113-6. Available from:

   Introduction Top

Benign prostatic hyperplasia (BPH) occurs in approxi­mately 50% of men in 5th decade and in 90% at the 9th decade of life. [1] BPH causing bladder outlet obstruction has two components - the static factor due to enlarged adenoma and the dynamic factor due to contraction of smooth mus­cles in the prostate, prostatic capsule, bladder neck and prostatic urethra. The hyperplasia in BPH is predominantly stromal of which smooth muscle constitutes 40% (Bartsch). [2] The degree of muscle tone in these areas are regulated by α-adrenergic receptors, as this gland is mainly innervated by adrenergic sympathetic nerves, α-adrenergic blockers have been shown to improve urinary flow and the irritative symptoms. [3] Caine [4],[5] first demonstrated the presence of these receptors in prostatic tissue while Furuga, [6] and Christensen [7] demonstrated the use of α-adrenergic antagonist in relieving outflow obstruction due to BPH. From 1976, α-adren­ergic blockers are in use (Cain) [8] . Since then many α-adren­ergic blockers are in use. The recent discovery of highly selective αl-a blockers and its use in management of BPH has greatly improved the efficacy of medical management of BPH. [9] Studies have shown that αl-a receptors are pre­dominant in human prostate (Lepor). [10]

Doxazocin, a 3rd generation α-blocker is one such highly selective drug now in use in BPH. It has a half life of 22 hours and has a relatively slow onset of action with peak plasma concentration being achieved in 2-6 hours after dosing (Rudi). [11] Plasma elimination of doxazocin is biphasic, the 1 st elimination phase occurring between 3 and 12 hours after administration, the 2 nd phase occurring after 20 hours after administration.

As a result of these features, doxazocin has a smooth onset of action when given once daily, [12] resulting in good patients compliance and not influenced by age or renal function. [13] Recent studies [14] have shown it to be safe, and effective drug in management of BPH, particularly in pa­tients with hypertension in whom it also greatly reduces the risk of coronary heart disease (CHD).

In our present open label study, we determine the safety and efficacy of doxazocin in management of BPH among patients not having absolute indication for surgery.

   Patients and Methods Top

240 consecutive patients having features of prostatism but not having absolute indication for surgery were in­ cluded in our studies with a 6-month follow up.

  • Patients suspected of having malignancy of prostate, chronic renal failure, neurogenic bladder, stricture urethra with significant hepatic and cardiovascular dysfunction were excluded from this study.
  • Previous history of taking drugs for BPH were also not included.
  • All the patients included in the study had a detailed history, clinical examination including per rectal ex­amination; and symptoms score following interna­tional prostate symptoms score (IPSS) pattern. This was followed by ultrasound estimation of weight of prostate in grams, postmicturation urine volume and uroflowmetry. The baseline maximum flow rate (MFR) was less than 12 ml/sec, average flow rate (AFR) less than 5 ml/sec, post micturating urine vol­ume more than 100 ml in our study.
  • A baseline blood biochemistry including liver func­tion test (LFT), kidney function test (KFT), lipid pro­file and serum PSA was done in all our patients.
  • Blood pressure record was done before and during therapy regularly.
  • A written informed consent was obtained from all the patients before starting the therapy.
  • 4 mg of doxazocin (Doxacard), once a day for 2 months was given to all our patients in a graduated manner.
  • During the 2-months' therapy all patients were asked to record their blood pressure (BP) regularly. Any adverse effects were also recorded during the treat­ment.
  • The patients were then followed up at 2-monthly in­tervals for next 6 months with records of their symptomtaology as per IPSS pattern. At the end of 8 months from starting the therapy, ultrasound of pros­tate weight, postmicturating urine volume, uroflow­metry, LFT, KFT, PSA and lipid profile was obtained and analysed.

   Results Top

Out of a total number of 240 patients there were 20 dropouts leaving a total 220 patients for analysis. The av­erage age of our patients was 67 years varying from 40 to 88 years. For uniformity of therapy, only I brand of doxazocin (Doxacard - Cipla) was used.

Symptom Score

Improvement in the symptoms was observed within 2 weeks of starting the therapy. At the end of the therapy 90% improvement in the obstructive and irritative symp­toms was observed. From the average initial IPSS of 17 the score fell to 6. At the end of 8th month a 75% im­provement in the subjective symptomatology was achieved [Table - 1].

Flow Rates

At the end of the therapy, the average maximum flow rate showed improvement by 5-5.5 ml/sec from baseline value of 10 ± 2 ml/sec reaching a good MFR of 15 ± 0.5 ml/sec, while the average mean flow rate showed improvement by 2.5-3 ml/sec from the baseline value of 4.5 ± 0.5 ml/sec reaching a good AFR of 7 ± 0.5 ml/sec. At the end of 8th month, on follow up MFR was 13 ± 0.5 ml/sec and AFR was 5.5 ± 0.5 ml/sec [Table - 2].

Residual Urine Volume

At the end of the therapy, there was a significant reduc­tion in the postmicturating urine volume by 36% while at the end of 8th month on follow-up there was a 26% re­duction in volume. No significant change in prostate size was observed; rather in a good number of patients, size of prostate showed increase in weight.

Adverse Events

Most of the adverse events were either mild to moderate in severity. The most common adverse effect was dizziness followed by vertigo, asthenia, headache, hypotension and dryness of mouth and skin [Table - 3].

Blood Pressure

Out of a total number of 220 patients, 99 patients (45%) were normotensive and 121 patients (55%) were hyper­tensive before therapy. The average fall in systolic/diastolic pressure was 20/10 mmHg among all hypertensive pa­tients, while the fall was within a range of 8/4 mmHg among normotensive patients respectively. None of the patients discontinued the therapy due to hypotension. There was moderate degree in fall of total serum choles­terol and low density lipoprotein but LFT and KFT did not show significant changes. Though the serum PSA level showed a fall, it was not of much clinical significance.

   Discussion Top

The standard treatment for BPH is surgery, making pros­tatectomy the 2nd most common surgical procedure in men aged over 50 years of age. Although the majority of the patients experience symptomatic improvement following prostatic surgery, several published studies have indicated that the long-term outcome is not as favorable as previ­ously assumed. [15],[16],[17] Again an increasing elderly popula­tion and escalating healthcare cost have motivated the search for non-surgical therapies for BPH. Different stud­ies have shown doxazocin improved MFR, which is re­garded as the most important objective efficacy parameter for BPH. In our study, similar observations were made. Significant subjective improvement in nocturia, hesitancy, urgency, intermittency and weak stream was achieved by doxazocin in our study as compared to others. We fol­lowed the IPSS pattern for clinical evaluation of our pa­tients. The IPSS is based on the AUA scale with an additional question about impact of symptoms on qual­ity of life. This score pattern is nowadays internationally accepted and widely followed.

The once daily dose schedule makes doxazocin admin­istration convenient especially in elderly males who are under other medications due to their other geriatric prob­lems, resulting in a good patient compliance.

Since more than 50% of patients of BPH have conco­mittant hypertension, doxazocin is very useful in reducing their blood pressure alongwith alleviating their prostatism symptoms. Among normotensive patients blood pressure change due to doxazocin is insignificant.

The moderate fall in serum triglycerides and cholesterol level in our study is similar to those reported by other au­thors. [18] Doxazocin has also other beneficial effects:

i) moderate decrease in total cholesterol, low density lipoprotein (LDL) and triglycerides' thereby reducing CHD risk factors;

ii) increased platelet activation;

iii) improved tissue plasminogen activator activity;

iv) decreased left ventricular hypertrophy;

Taken together, the above beneficial effects of doxazocin can significantly reduce the calculated risk of CHD,[19] which is a unique aspect of doxazocin.

   Conclusions Top

Medical management of BPH has a valuable role to play in patients with mild to moderate prostatism. Our study has shown that a daily dose of 4 mg of doxazocin (Doxa­card), a 3rd generation α-adrenergic antagonist is not only well tolerated and safe but also greatly improves the urine flow rate and symptoms of prostatism apart from having beneficial effects like reducing the risk of CHD with a very low adverse effect.

   References Top

1.Walsh PC. Benign prostatic hyperplasia. In Campbell's Urology 6ih ed. 1992; chapt. 25(1): 1009-1029.  Back to cited text no. 1    
2.Bartsch G, Muller HJ et al. Light microscopic sterological analysis of the normal human prostate and BPH.  Back to cited text no. 2    
3.Hedlund H, Anderson KE. Alpha adrenoreceptors and muscarine receptors in the isolated human prostate. J Urol 1985; 134: 1291­-1298.  Back to cited text no. 3    
4.Caine M, Raz Si et al. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193.  Back to cited text no. 4    
5.Caine M, Schuger L. The capsule in benign prostatic hypertrophy. Dept of Health & Human Services, National Inst of Health Publi­cation 1987; No. 87-2881, 221.  Back to cited text no. 5    
6.Furuya S, Abiko et al. Alpha adrenergic activity and urethral pres­sure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836.  Back to cited text no. 6    
7.Christensen M, Bruskewitz RC. Clinical manifestation of benign prostatic hyperplasia and indication for therapeutic intervention. Urol Clin N Am 1990; 17: 509.  Back to cited text no. 7    
8.Caine M, Perlberg S. The use of alpha adrenergic blockers in be­nign prostatic obstruction. Br J Urol 1976; 48: 225.  Back to cited text no. 8    
9.Pool SL. Role of the sympathetic nervous system in hypertension and BPH. Br J Clin Pract 1994; 74: 13.  Back to cited text no. 9    
10.Leper H, Machi G. Relative efficacy of terazocin vs terazocin and flutamide for the treatment of symptomatic BPH. Prostate 1992; 20: 89.  Back to cited text no. 10    
11.Rudi A, Janknegt. Profile of doxazocin in patients with BPH. Scand J Urol Neph 1995; 29: 21-27.  Back to cited text no. 11    
12.Elliott HL, Mededitti. Pharmacokinetic overview of doxazocin. Am J Cardiol 1987; 59: 78G.  Back to cited text no. 12    
13.Young RA, Brogday RN. Doxazocin - A review of its pharmaco­dynamic and pharmacokinetic properties and therapeutic efficacy in mild to moderate hypertension. Drugs 1988; 35: 525-541.  Back to cited text no. 13    
14.Janknegt RA, Chapple CR. Efficacy and safety of the al-blocker doxazocin in the treatment of benign prostatic hyperplasia. Analy­sis of 5 studies - doxazocin study group. Eur Urol 1993; 24: 319.  Back to cited text no. 14    
15.Barry MJ, Mulley AG et al. Watchful waiting vs immediate transure­thral resection for symptomatic prostatism. The importance of pa­tients' preferences. JAMA 1988; 259: 3010-17.  Back to cited text no. 15    
16.Fawler FJ Jr; Wennberg JE et al. Symptoms status and quality of life following prostatectomy. JAMA 1988; 259: 3018-22.  Back to cited text no. 16    
17.Roos NP, Wennberg JE et al. Mortality and reoperation after open and transurethral resection of prostate for BPH. N Eng J Med 1989; 320: 1120-24.  Back to cited text no. 17    
18.Pool J. Effects of doxazocin in serum lipids - A review of the clini­cal data and molecular basis for altered lipid metabolism. Am Heart J 1991; 121: 251.  Back to cited text no. 18    
19.Levy D, Wilson PWF et al. Stratifying patients at risk from coro­nary disease, new insight from the Framingham heart study. Am Heart J 1990; 119: 712-17.  Back to cited text no. 19    


  [Table - 1], [Table - 2], [Table - 3]


Print this article  Email this article
Previous article Next article


   Next article
   Previous article 
   Table of Contents
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    [PDF Not available] *
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Patients and Methods
    Article Tables

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal